Article

Using genetic drug-target networks to develop new drug hypotheses for major depressive disorder

2018-04-18

Abstract excerpt

The major depressive disorder (MDD) working group of the Psychiatric Genomics Consortium (PGC) has published a genome-wide association study (GWAS) for MDD in 130,664 cases, identifying 44 risk variants. We used these results to investigate potential drug targets and repurposing opportunities. We built easily interpretable bipartite drug-target networks integrating interactions between drugs and their targets, gen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6967fdfc-c822-5d43-a358-c839cadb1594
DOI: 10.1101/304113

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Using genetic drug-target networks to develop new drug hypotheses for major depressive disorderDOI 10.1101/304113Read

Genetically informed drug target prioritisation and repurposing for major depressive disorderSemantic proximity Read

Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposingSemantic proximity Read

Identifying Potential Novel Pathways and Therapeutic Targets of Major Depressive Disorder with Functional GenomicsSemantic proximity Read

Translating GWAS Findings Into Therapies For Depression And Anxiety Disorders: Drug Repositioning Using Gene-Set Analyses Reveals Enrichment Of Psychiatric Drug ClassesSemantic proximity Read

Genetic Landscape of Major Depressive Disorder: Assessment of Potential Diagnostic and Antidepressant Response MarkersSemantic proximity Read

Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.Semantic proximity Read

Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression RiskSemantic proximity Read

Genome-wide pathway analysis in major depressive disorder.Semantic proximity Read

Pathway-based polygenic risk implicates GO: 17144 drug metabolism in recurrent depressive disorderSemantic proximity Read

Pathway and network embedding methods for prioritizing psychiatric drugsSemantic proximity Read

Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and CompoundsSemantic proximity Read

Integrating Multi-Omics Summary Data Identifies Candidate Molecular Mechanisms for Major Depression.Semantic proximity Read